

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUNPHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2013 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

30 October 2013

As at the date of this announcement, the executive directors are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Zhang Guozheng, Mr. Wang Pinliang and Ms. Kang Lan; and the independent non-executive directors are Mr. Han Jiong, Dr. Zhang Weijiong, Mr. Li Man-kiu Adrian David and Mr. Cao Huimin.

* *For identification purposes only*

§1 IMPORTANT NOTICE

- 1.1 The board of directors and the supervisory committee of the Company, and its directors, supervisors and senior management warrant that this report does not contain any false information, misleading statements or material omission and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents herein contained.
- 1.2 All Directors of the Company attended the Board meeting.
- 1.3 Chen Qiyu, the Chairman of the Company, Hongfei Jia, the Chief Financial Officer and Yan Jia, the Director of the Accounting Department (Accounting Officer) duly declare that they warrant the truthfulness and completeness of the financial report contained in this quarterly report.
- 1.4 The financial statements of the third quarterly report of the Group have not been audited.

§2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDERS OF THE COMPANY

2.1 Major financial information

Unit: Yuan Currency: RMB

	As at the end of the Reporting Period	As at the end of the previous year	Change recorded at the end of the Reporting Period compared with the end of the previous year (%)
Total assets (RMB)	27,589,580,696.34	25,507,140,466.01	8.16
Owners' equity (or shareholders' equity) (RMB)	14,593,258,574.79	13,558,792,587.27	7.63
	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Year-on-year change (%)
Net cash flow generated from operating activities (RMB)	467,404,025.74	415,490,491.69	12.49
	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Year-on-year change (%)
Operating revenue(RMB) (Note)	7,070,780,938.31	5,387,845,935.96	31.24
Net profit attributable to shareholders of the listed company (RMB)	1,389,079,631.65	1,093,223,251.90	27.06
Net profit attributable to shareholders of the listed company after deducting extraordinary gain and loss (RMB/share)	770,933,187.12	637,420,180.98	20.95
Weighted average return on net assets (%)	10.14	10.93	Decreased by 0.79 percentage point
Basic earnings per share (RMB/share)	0.62	0.57	8.77
Diluted earnings per share (RMB/share)	0.62	0.57	8.77

Note: The significant increase in operating revenue as compared with those of the same period of the previous year were mainly due to the increase in sales of pharmaceutical manufacturing and manufacturing of medical diagnosis and medical devices, as well as the contribution from the newly acquired subsidiaries.

After deducting extraordinary items and amounts:

Unit: Yuan Currency: RMB

Items	The Reporting Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period	Description
Gain or loss from disposal of non-current assets	10,251,236.77	596,825,644.44	
Government subsidies included in gain and loss of the current period, excluding those closely related to the ordinary business of the Company and granted in fixed amount or fixed quota in conformity with the national policies and standards	2,878,850.90	13,168,079.40	
Gain and loss on change in fair value of financial assets and liabilities held for trading, and investment gain realized from disposal of financial assets and liabilities held for trading and available-for-sale financial assets, other than those from effective hedging activities relating to the Company's ordinary course of business	80,220,837.82	218,571,999.35	Mainly due to the disposal of available-for-sale financial assets and the fluctuation of prices of financial assets held for trading of the Group during the Reporting period
Other non-operating income and expenses other than the foregoing items	462,524.66	-1,915,596.10	
Effect of income tax	-23,279,225.73	-195,412,839.05	
Impact on minority interests (after tax)	-7,678,145.29	-13,090,843.51	
Total	62,856,079.13	618,146,444.53	

2.2 Total number of shareholders, the shareholding status of the Top 10 shareholders and the Top 10 unrestricted shareholders of the Company at the end of the reporting period

Unit: Share

Total number of shareholders				111,905	
The shareholding status of the Top 10 shareholders					
Name of the shareholder	Capacity	Shareholding (%)	Total number of shares held	Number of restricted shares held	Number of shares pledged or frozen
Shanghai Fosun High Technology (Group) Co., Ltd.	Domestic non-state owned legal entity	41.09	920,641,314	0	None
HKSCC NOMINEES LIMITED (note)	Overseas legal entity	14.96	335,255,500	0	Unknown
China Life Insurance Co., Ltd. — Dividend-Personal Dividend — 005L — FH002 Shanghai	Unknown	1.69	37,868,964	0	None
China Construction Bank — Hua An Hong Li Stock Securities Investment Fund	Unknown	1.44	32,188,808	0	None
Industrial and Commercial Bank of China — Hui Tian Fu Cheng Long Focus Stock Securities Investment Fund	Unknown	0.95	21,318,308	0	None
Industrial and Commercial Bank of China — Jing Shun Great Wall selected blue-chip Stock Securities Investment Fund	Unknown	0.85	19,120,000	0	None
China Merchants Bank Co., Ltd. — EverBright Bao De Xin Superiority Allocation Stock Securities Investment Fund	Unknown	0.81	18,110,252	0	None
National Social Security Fund 104 portfolio	Unknown	0.74	16,599,805	0	None
Bank of Communications — Peng Hua China 50 Open-end Securities Investment Fund	Unknown	0.46	10,199,839	0	None
Bank of Communications — An Shun Securities Investment Fund	Unknown	0.45	10,000,000	0	None

The Top 10 unrestricted shareholders of tradable shares		
Name of the shareholder (in full)	Number of unrestricted tradable shares held at the end of the reporting period	Type and number of shares
Shanghai Fosun High Technology (Group) Co., Ltd.	920,641,314	RMB ordinary shares
HKSCC NOMINEES LIMITED <i>(note)</i>	335,255,500	Overseas listed foreign shares
China Life Insurance Co., Ltd. — Dividend — Personal Dividend — 005L — FH002 Shanghai	37,868,964	RMB ordinary shares
China Construction Bank — Hua An Hong Li Stock Securities Investment Fund	32,188,808	RMB ordinary shares
Industrial and Commercial Bank of China — Hui Tian Fu Cheng Long Focus Stock Securities Investment Fund	21,318,308	RMB ordinary shares
Industrial and Commercial Bank of China — Jing Shun Great Wall selected blue-chip Stock Securities Investment Fund	19,120,000	RMB ordinary shares
China Merchants Bank Co., Ltd. — EverBright Bao De Xin Superiority Allocation Stock Securities Investment Fund	18,110,252	RMB ordinary shares
National Social Security Fund 104 portfolio	16,599,805	RMB ordinary shares
Bank of Communications — Peng Hua China 50 Open-end Securities Investment Fund	10,199,839	RMB ordinary shares
Bank of Communications — An Shun Securities Investment Funds	10,000,000	RMB ordinary shares
Description of the related relationship or concerted action of the above shareholders	The fund trustee of Industrial and Commercial Bank of China — Hui Tian Fu Cheng Long Focus Stock Securities Investment Fund and Industrial and Commercial Bank of China — Jing Shun Great Wall selected blue-chip Stock Securities Investment Fund are both Industrial and Commercial Bank of China Limited; The fund trustee of Bank of Communications — Peng Hua China 50 Open-end Securities Investment Fund and Bank of Communications — An Shun securities investment funds are both Bank of Communications Co., Ltd.; The fund manager of China Construction Bank — Hua An Hong Li Stock Securities Investment Fund and Bank of Communications — An Shun securities investment funds are both Hua An Fund Management Co., Ltd.; The fund manager of National Social Security Fund 104 portfolio and Bank of Communications — Peng Hua China 50 Open-end Securities Investment Fund are both Penghua Fund Management Co., Ltd.; The Company is not aware of any related relationship and concerted action between any of other shareholders of tradable shares.	

Note: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Nominees Limited Company, is holding shares on behalf of multiple clients.

§3 SIGNIFICANT EVENTS

3.1 Significant changes in major financial statement items and financial indicators of the Group and the reasons thereof

Applicable Not Applicable

Unit: Yuan Currency: RMB

Balance Sheet				
Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year	Ratio of change	Reasons
Cash and cash equivalents	2,485,783,000.50	4,972,524,758.70	-50%	Mainly due to the increase in payment for investment during the first three quarters of 2013
Trade receivable	1,316,781,579.78	907,307,576.06	45%	Mainly due to the changes in the scope of consolidation and the enlargement of the sales scale of the company during the first three quarters of 2013
Interest receivable	7,615,057.77	17,674,707.55	-57%	Mainly due to the recovery of interest due during the first three quarters of 2013
Intangible assets	2,368,367,750.12	1,752,799,860.87	35%	Mainly due to the changes in the scope of consolidation during the first three quarters of 2013
Development expenditures	42,946,124.18	29,475,413.33	46%	Mainly due to the increase in the R&D investment during the first three quarters of 2013
Goodwill	2,710,407,586.05	1,661,770,763.96	63%	Mainly due to the changes in the scope of consolidation during the first three quarters of 2013
Other non-current assets	236,069,350.21	100,654,101.39	135%	Mainly due to the increased prepaid land premium, the increased payment for engineering equipment and the changes in the scope of consolidation during the first three quarters of 2013
Deferred income tax assets	72,033,067.63	31,482,514.80	129%	Mainly due to the changes in the scope of consolidation during the first three quarters of 2013
Short-term loans	1,199,559,074.08	519,422,250.00	131%	Mainly due to the increase in short-term debt during the first three quarters of 2013
Dividends payable	12,240,519.57	4,725,748.28	159%	Mainly due to the non-payment of the accrual of dividends payable to minority shareholders during the first three quarters of 2013
Other current liabilities	33,196,473.53	526,384,431.15	-94%	Mainly due to the payment of short-term financing bonds during the first three quarters of 2013

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Operating revenue	7,070,780,938.31	5,387,845,935.96	31%	Mainly due to the increase in sales of pharmaceutical manufacturing and manufacturing of medical diagnosis and medical devices, as well as the contribution from the newly acquired subsidiaries during the first three quarters of 2013
Operating costs	3,957,631,876.59	3,005,217,397.09	32%	Mainly due to the increase in sales of pharmaceutical manufacturing and manufacturing of medical diagnosis and medical devices, as well as the changes in the scope of consolidation during the first three quarters of 2013
Gains from changes in fair value (“-” indicating loss)	39,511,717.28	-14,636,854.56	N/A	Mainly due to the fluctuation of stock price of Financial assets held for trading during the first three quarters of 2013
Income tax expenses	313,206,671.22	202,061,631.73	55%	Mainly due to the increase in income tax charge in respect of the investment gain arising from disposal of the Group’s equity interest in its associates during the first three quarters of 2013
Non-operating revenue	72,257,721.95	33,558,889.22	115%	Mainly due to the increase in receipt of government subsidies during the first three quarters of 2013
Other comprehensive income	285,252,496.15	-436,322,994.17	N/A	Mainly due to the movements of fair values of the Group’s available-for-sale financial assets during the first three quarters of 2013

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period	From the beginning of the previous year to the end of the Reporting Period of the previous year	Ratio of change	Reasons
	(Jan – Sep)	(Jan – Sep)		
Net cash flow generated from investing activities	-1,757,461,995.58	-368,977,652.38	376%	Mainly due to the increase in cash paid for investment during the first three quarters of 2013

3.2 Analysis and explanation of the progress, impact and solution of major events

√ Applicable □ Not applicable

On 26 September 2013, the fifth meeting (extraordinary) of the sixth session of the Board and the 2013 3rd meeting (extraordinary) of the sixth session of the Supervisory Committee, had considered and approved the proposal of Restricted Share Incentive Scheme (draft) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*. On 25 October 2013, the CSRC issued a letter of no objection for the “Opinion on the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Restrictive A Share Incentive Scheme” (Shang Shi Yi Bu Han [2013] No. 774). According to the feedback of the CSRC, the Board amended, supplemented and revised the initial draft, and prepared the Restricted Share Incentive Scheme (revised draft) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* based on the actual situation of the Company. The ninth meeting (regular meeting) of the sixth session of the Board and the 2013 fourth meeting (regular meeting) of the sixth session of

the Supervisory Committee, had considered and approved the Restricted Share Incentive Scheme (revised draft) of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*. The above Share Incentive Scheme (revised draft) is subject to the shareholder's approval at the general meeting.

3.3 Fulfillment of undertakings by the Company, shareholders and de facto controllers

Applicable Not Applicable

3.4 Warning on any potential loss in accumulated net profit for the period from the beginning of the year to the end of the next reporting period or any material changes in accumulated net profit as compared with the same period of the previous year and the reason thereof

Applicable Not Applicable

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal representative: **Chen Qiyu**

30 October 2013

§4 APPENDICES

4.1

Consolidated balance sheet

30 September 2013

Prepared by: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	2,485,783,000.50	4,972,524,758.70
Settlement reserves		
Loans to banks or other financial institutions		
Financial assets held for trading	258,756,754.96	224,834,307.14
Bills receivable	293,416,923.81	306,710,161.00
Trade receivable	1,316,781,579.78	907,307,576.06
Prepayments	279,681,295.65	239,307,192.55
Premiums receivable		
Reinsurance accounts receivable		
Reinsurance contract reserve receivable		
Interest receivable	7,615,057.77	17,674,707.55
Dividends receivable	15,697,156.84	12,298,837.25
Other receivables	467,158,390.71	423,080,420.35
Purchase and sell-back of financial assets		
Inventories	1,629,432,467.70	1,273,438,729.51
Non-current assets due within one year		
Other current assets	4,495,956.06	4,341,123.93
Total current assets	6,758,818,583.78	8,381,517,814.04
Non-current assets:		
Provision of entrusted loans and advances		
Available-for-sale financial assets	1,665,410,046.04	1,454,122,878.62
Held-to-maturity investment		
Long-term receivables		
Long-term equity investments	9,668,859,344.13	8,593,169,673.95
Investment properties		
Fixed assets	2,987,437,844.46	2,595,295,851.85
Construction in progress	1,055,727,109.86	881,963,019.23
Project supplies	4,804,835.81	2,462,935.26
Disposal of fixed assets		
Productive biological assets		
Oil and gas assets		
Intangible assets	2,368,367,750.12	1,752,799,860.87
Development expenditures	42,946,124.18	29,475,413.33
Goodwill	2,710,407,586.05	1,661,770,763.96
Long-term deferred expenditures	18,699,054.07	22,425,638.71

Consolidated balance sheet (Continued)

30 September 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Non-current assets (Continued):		
Deferred income tax assets	72,033,067.63	31,482,514.80
Other non-current assets	236,069,350.21	100,654,101.39
Total non-current assets	20,830,762,112.56	17,125,622,651.97
Total assets	27,589,580,696.34	25,507,140,466.01
Current liabilities:		
Short-term loans	1,199,559,074.08	519,422,250.00
Borrowings from the central bank		
Deposits from customers and inter-bank deposits		
Loans from banks and other financial institutions		
Financial liabilities held for trading		
Bills payable	102,971,927.98	127,315,857.43
Trade payable	1,004,684,182.01	776,405,723.39
Receipts in advance	156,875,655.39	203,474,939.29
Gain on disposal of repurchased financial assets		
Fees and commissions payable		
Wages payable	159,591,990.95	141,401,257.23
Tax payable	185,408,807.41	161,980,223.43
Interest payable	159,713,834.54	154,068,466.58
Dividends payable	12,240,519.57	4,725,748.28
Other payables	917,421,953.27	922,144,318.20
Reinsurance accounts payables		
Insurance contract reserve payable		
Amount paid for agency securities trading		
Amount paid for agency securities underwriting		
Non-current liabilities due within one year	360,909,090.00	355,909,090.00
Other current liabilities	33,196,473.53	526,384,431.15
Total current liabilities	4,292,573,508.73	3,893,232,304.98
Non-current liabilities:		
Long-term loans	125,909,100.00	216,818,190.00
Bonds payable	4,070,832,033.25	4,063,347,254.54
Long-term payables	831,130,594.42	612,229,845.06
Specific payables	36,804,357.07	15,391,973.76
Accrued liabilities		
Deferred income tax liabilities	1,689,622,977.70	1,359,937,859.61
Other non-current liabilities	60,003,955.34	41,534,601.93
Total non-current liabilities	6,814,303,017.78	6,309,259,724.90
Total liabilities	11,106,876,526.51	10,202,492,029.88

Consolidated balance sheet (Continued)

30 September 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-in capital (or share capital)	2,240,462,364.00	2,240,462,364.00
Capital reserve	4,396,998,107.25	4,287,287,930.01
Less: treasury shares		
Specific reserve		
Surplus reserve	1,338,476,598.49	1,338,476,598.49
General risk provision		
Unappropriated profits	6,621,610,997.36	5,703,028,462.15
Foreign currency translation difference	-4,289,492.31	-10,462,767.38
Total equity attributable to the owners of the Parent company	14,593,258,574.79	13,558,792,587.27
Minority interests	1,889,445,595.04	1,745,855,848.86
Total equity attributable to the owners	16,482,704,169.83	15,304,648,436.13
Total liabilities and equity attributable to the owners	27,589,580,696.34	25,507,140,466.01

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia

Balance sheet of the Parent Company
30 September 2013

Prepared by: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	967,810,425.06	2,804,108,583.37
Financial assets held for trading		
Bills receivable		
Trade receivable		
Prepayments		
Interest receivable	112,185,785.22	98,972,778.68
Dividends receivable	24,240,000.00	
Other receivables	1,207,151,982.57	941,562,545.17
Inventories	517,042.01	516,409.53
Non-current assets due within one year		
Other current assets	280,000,000.00	250,000,000.00
Total current assets	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
Available-for-sale financial assets		
Held-to-maturity investment		
Long-term receivables		
Long-term equity investments	5,471,340,934.74	4,173,763,622.82
Investment properties		
Fixed assets	20,153,012.47	20,815,349.96
Construction in progress		
Project supplies		
Disposal of fixed assets		
Productive biological assets		
Oil and gas assets		
Intangible assets	3,215,662.67	3,496,198.41
Development expenditures		
Goodwill		
Long-term deferred expenditures		
Deferred income tax assets		
Other non-current assets	4,470,831,299.40	4,035,133,683.09
Total non-current assets	9,965,540,909.28	8,233,208,854.28
Total assets	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30 September 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Short-term loans		
Financial liabilities held for trading		
Bills payable		
Trade payable		
Receipts in advance		
Wages payable	26,138,331.81	29,108,232.08
Tax payable	16,833,088.84	5,188,721.77
Interest payable	155,509,208.37	152,405,396.96
Dividends payable		
Other payables	554,584,851.12	46,800,203.98
Non-current liabilities due within one year	360,000,000.00	355,000,000.00
Other current liabilities		499,375,000.00
Total current liabilities	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
Long-term loans	125,000,000.00	165,000,000.00
Bonds payable	4,070,832,033.25	4,063,347,254.54
Long-term payables		
Specific payables		
Accrued liabilities		
Deferred income tax liabilities		
Other non-current liabilities	2,275,000.00	2,500,000.00
Total non-current liabilities	4,198,107,033.25	4,230,847,254.54
Total liabilities	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-in capital (or share capital)	2,240,462,364.00	2,240,462,364.00
Capital reserve	3,754,014,307.53	3,755,009,519.04
Less: treasury shares		
Specific reserve		
Surplus reserve	305,635,420.68	305,635,420.68
General risk provision		
Unappropriated profits	946,161,538.54	708,537,057.98
Total equity attributable to the owners (or equity attributable to shareholders)	7,246,273,630.75	7,009,644,361.70
Total liabilities and equity attributable to the owners (or equity attributable to shareholders)	12,557,446,144.14	12,328,369,171.03

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia

4.2

Consolidated Income Statement

January — September 2013

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Total operating revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Including: Operating revenue	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
Interest income				
Earned premiums				
Fees and commission income				
II. Total operating costs	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
Including: Operating costs	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
Interest expenses				
Fees and commission expenses				
Premiums refund				
Compensation payout, net				
Net provision drawn for insurance contract				
Policy dividend payment				
Amortized reinsurance expenditures				
Business tax and surcharges	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
Selling expenses	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
Administrative expenses	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
Finance costs	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
Asset impairment losses	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Plus: Gains from changes in fair value (“-” indicating loss)	-548,949.75	-4,627,534.57	39,511,717.28	-14,636,854.56
Investment income (“-” indicating loss)	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
Including: Gains from investments in associated companies and joint ventures	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
Foreign exchange gains (“-” indicating loss)				
III. Operating profit (“-” indicating loss)	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Plus: Non-operating revenue	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
Less: Non-operating expenses	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
Including: Loss on disposal of non-current assets	260,198.27	-243,201.72	979,886.77	946,040.98

Consolidated Income Statement (Continued)

January — September 2013

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
IV. Total profit (“–” indicating total loss)	482,787,484.27	531,051,112.73	1,933,877,431.89	1,518,280,517.90
Less: Income tax expenses	64,268,069.49	72,601,703.57	313,206,671.22	202,061,631.73
V. Net profit (“–” indicating net loss)	418,519,414.78	458,449,409.16	1,620,670,760.67	1,316,218,886.17
Net profit attributable to the owners of the Parent company	335,938,421.01	391,456,294.41	1,389,079,631.65	1,093,223,251.90
Gains/losses of minority shareholders	82,580,993.77	66,993,114.75	231,591,129.02	222,995,634.27
VI. Earnings per share:				
(1) basic earnings per share	0.15	0.21	0.62	0.57
(2) diluted earnings per share	0.15	0.21	0.62	0.57
VII. Other comprehensive income	238,213,769.74	–339,947,647.08	285,252,496.15	–436,322,994.17
VIII. Total comprehensive income	656,733,184.52	118,501,762.08	1,905,923,256.82	879,895,892.00
Total comprehensive income attributable to the owners of the Parent company	569,470,627.56	62,492,107.12	1,676,404,370.90	668,358,678.61
Total comprehensive income attributable to minority interests	87,262,556.96	56,009,654.96	229,518,885.92	211,537,213.39

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia

Income Statement of the Parent Company
January — September 2013

Prepared by: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Operating revenue				
Less: Operating costs				
Business tax and surcharges				
Selling expenses				
Administrative expenses	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
Finance costs	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
Asset impairment losses				
Plus: Gains from changes in fair value ("–" indicating loss)				
Investment income ("–" indicating loss)	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
Including: Gains from investments in associated companies and joint ventures	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. Operating profit ("–" indicating loss)	–34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Plus: Non-operating revenue	76,900.00	234,093.38	236,049.11	734,093.38
Less: Non-operating expenses		–570,000.00	2,514,544.42	860,000.00
Including: Loss on disposal of non-current assets			5,725.77	
III. Total profit ("–" indicating total loss)	–34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
Less: Income tax expenses				
IV. Net profit ("–" indicating net loss)	–34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
V. Earnings per share:				
(1) basic earnings per share				
(2) diluted earnings per share				
VI. Other comprehensive income			51,779.40	27,699,470.25
VII. Total comprehensive income	–34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia

4.3

Consolidated Statement of Cash Flow

January – September 2013

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	8,353,071,465.55	5,897,514,534.63
Net increase of deposits from customers and inter-bank deposits		
Net increase of borrowings from the central bank		
Net increase of loans from other financial institutions		
Cash received as premiums of original insurance contract		
Net cash received from reinsurance business		
Net increase of policy holder deposits and investment		
Net increase of disposal of financial assets held for trading		
Cash received from interests, fees and commissions		
Net increase of loans from banks and other financial institutions		
Net increase of capital from repurchase business		
Refund of taxes and levies	70,747,841.37	32,232,231.07
Other cash received relating to operating activities	195,314,752.07	217,699,989.08
Sub-total of cash inflow from operating activities	8,619,134,058.99	6,147,446,754.78
Cash paid for purchasing goods and receiving services	4,942,760,855.58	3,240,780,364.81
Net increase of customers' loans and advances		
Net increase of deposits in the central bank and inter-bank deposits		
Cash paid for compensation payout under original insurance contracts		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to and for the benefit of employees	894,408,458.48	722,618,949.19
Taxes and levies paid	768,933,645.45	600,550,345.09
Other cash paid relating to operating activities	1,545,627,073.74	1,168,006,604.00
Sub-total of cash outflow from operating activities	8,151,730,033.25	5,731,956,263.09
Net cash flow arising from operating activities	467,404,025.74	415,490,491.69
II. Cash flow generated from investing activities:		
Cash received from investment recovery	388,982,617.89	846,066,316.51
Cash received from return on investments	279,562,076.99	263,995,916.83
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	5,409,794.89	9,309,000.09
Net cash received from disposal of subsidiaries and other operating segments		
Other cash received relating to investing activities	644,097,500.00	95,179,169.35
Sub-total of cash inflow from investing activities	1,318,051,989.77	1,214,550,402.78

Consolidated Statement of Cash Flow (Continued)

January – September 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
II. Cash flow generated from investing activities (Continued):		
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	711,664,658.89	839,693,736.40
Cash paid for investments	251,949,461.45	734,761,521.45
Net increase of pledged loans		
Net cash paid for acquisition of subsidiaries and other operating segments	2,011,879,515.78	
Other cash paid relating to investing activities	100,020,349.23	9,072,797.31
Sub-total of cash outflow from investing activities	3,075,513,985.35	1,583,528,055.16
Net cash flow generated from investing activities	-1,757,461,995.58	-368,977,652.38
III. Cash flow generated from financing activities:		
Cash received from capital contribution	2,088,710.98	761,199.00
Including: cash received by subsidiaries from investments of minority interests	2,088,710.98	761,199.00
Cash received from borrowings	1,302,361,982.24	1,022,152,808.76
Cash received from issuing bonds		1,486,950,000.00
Other cash received relating to financing activities	329,448,475.13	262,541,891.46
Sub-total of cash inflow from financing activities	1,633,899,168.35	2,772,405,899.22
Cash paid for debts settlement	1,221,891,677.53	2,628,044,486.20
Cash paid for the distribution of dividends, profits or interest payments	950,844,046.86	601,916,917.03
Including: dividends and profits paid by subsidiaries to minority interests	702,264,204.84	366,813,171.49
Other cash paid relating to financing activities	48,488,630.70	101,408,014.93
Sub-total of cash outflow from financing activities	2,221,224,355.09	3,331,369,418.16
Net cash flow generated from financing activities	-587,325,186.74	-558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-25,426,268.76	-4,569,909.53
V. Net increase of cash and cash equivalents	-1,902,809,425.34	-517,020,589.16
Plus: Opening balance of cash and cash equivalents	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia

Statement of Cash Flow of the Parent Company
January – September 2013

Prepared by: **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

Unit: Yuan Currency: RMB Type of audit : Unaudited

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services		
Refund of taxes and levies		
Other cash received relating to operating activities	37,439,681.37	40,008,504.21
Sub-total of cash inflow from operating activities	37,439,681.37	40,008,504.21
Cash paid for purchasing goods and receiving services		
Cash paid to and for the benefit of employees	47,805,533.82	43,283,375.23
Taxes and levies paid	20,609,862.43	11,891,537.59
Other cash paid relating to operating activities	31,711,001.63	44,174,769.12
Sub-total of cash outflow from operating activities	100,126,397.88	99,349,681.94
Net cash flow arising from operating activities	-62,686,716.51	-59,341,177.73
II. Cash flow generated from investing activities:		
Cash received from investment recovery	39,904,000.00	59,856,000.00
Cash received from return on investments	794,850,316.23	463,000,000.00
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	96,000.00	11,400.00
Net cash received from disposal of subsidiaries and other operating segments		
Other cash received relating to investing activities	638,137,500.00	
Sub-total of cash inflow from investing activities	1,472,987,816.23	522,867,400.00
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,762,713.09	1,102,964.27
Cash paid for investments	709,566,469.16	20,000,000.00
Net cash paid for acquisition of subsidiaries and other operating segments	459,096,900.00	
Other cash paid relating to investing activities		
Sub-total of cash outflow from investing activities	1,170,426,082.25	21,102,964.27
Net cash flow generated from investing activities	302,561,733.98	501,764,435.73

Statement of Cash Flow of the Parent Company (Continued)

January – September 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
III. Cash flow generated from financing activities:		
Cash received from capital contribution		
Cash received from borrowings	255,115,078.77	
Cash received from issuing bonds		1,486,950,000.00
Other cash received relating to financing activities	1,904,031,173.98	4,295,169,165.49
Sub-total of cash inflow from financing activities	2,159,146,252.75	5,782,119,165.49
Cash paid for debts settlement	790,115,078.77	454,000,000.00
Cash paid for the distribution of dividends, profits or interest payments	674,744,025.09	302,177,196.32
Other cash paid relating to financing activities	2,109,471,293.35	5,478,222,986.00
Sub-total of cash outflow from financing activities	3,574,330,397.21	6,234,400,182.32
Net cash flow generated from financing activities	-1,415,184,144.46	-452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-22,851,531.32	
V. Net increase of cash and cash equivalents	-1,198,160,658.31	-9,857,758.83
Plus: Opening balance of cash and cash equivalents	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

Legal Representative of the
Company: Chen Qiyu

Chief Financial Officer:
Hongfei Jia

Director of the Accounting
Department: Yan Jia